Storia in 2 fonti

Ivonescimab Plus Chemotherapy Demonstrates Significant Overall Survival Benefit Versus Durvalumab Plus Chemotherapy in First-Line Biliary Tract Cancer: HARMONi-GI1 Meets Primary Endpoint

Raccontata da

morningstar.com

global.chinadaily.com.cn

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

morningstar.comStai leggendo10 h fa

Ivonescimab Plus Chemotherapy Demonstrates Significant Overall Survival Benefit Versus Durvalumab Plus…

Ivonescimab Plus Chemotherapy Demonstrates Significant Overall Survival Benefit Versus Durvalumab Plus Chemotherapy in First-Line Biliary Tract Cancer: HARMONi-GI1 Meets Primary Endpoint

originale

global.chinadaily.com.cn8 h fa

Chinese cancer treatment shows survival edge in trial

Chinese biotech firm Akeso Inc has announced positive interim results from a registrational Phase-3 trial, showing that its home-grown bispecific antibody ivonescimab combined with chemotherapy delivers statistically…

Ivonescimab Plus Chemotherapy Demonstrates Significant Overall Survival Benefit Versus Durvalumab Plus Chemotherapy in First-Line Biliary Tract Cancer: HARMONi-GI1 Meets Primary Endpoint

Confronto fonti

Ivonescimab Plus Chemotherapy Demonstrates Significant Overall Survival Benefit Versus Durvalumab Plus…

Chinese cancer treatment shows survival edge in trial

Timeline cronologica

Ivonescimab Plus Chemotherapy Global Phase III HARMONi Primary Analysis Results Published in The Lancet Oncology

Ivonescimab Plus Chemotherapy Demonstrates Significant Overall Survival Benefit Versus Durvalumab Plus Chemotherapy in First-Line Biliary…

Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Durvalumab Plus Chemotherapy in…

Chinese cancer treatment shows survival edge in trial